Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Vessix Vascular Inc. Stories

2012-11-08 12:27:14

LAGUNA HILLS, Calif., Nov. 8, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has signed a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX). The acquisition is expected to close by the end of November 2012. The agreement calls for an upfront payment of $125 million, plus $300 million in additional clinical and sales-based...

2012-11-08 08:34:32

NATICK, Mass., Nov. 8, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive agreement to acquire Vessix Vascular, Inc., a privately held company based in Laguna Hills, California. Vessix Vascular has developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension. The acquisition is expected to close by the end of November 2012....

2012-10-22 07:30:40

LAGUNA HILLS, Calif., Oct. 22, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami. On October 25, Dr. Eric Wyffels of the...

2012-10-02 06:26:20

LAGUNA HILLS, Calif., Oct. 2, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. Vessix was chosen as one of the Fierce 15 based, in part, on the innovation, creativity and promise of the Vessix V2 Renal Denervation...

2012-05-01 02:29:57

LAGUNA HILLS, Calif., May 1, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System(TM) for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to...

2012-04-12 02:37:48

LAGUNA HILLS, Calif., April 12, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that veteran medical device sales and marketing executive Michael D. Gioffredi has been named Chief Commercialization Officer. Gioffredi has worked as an executive in the medical device industry for over 25 years and for the past six years served as Senior Vice President of Sales and...

2012-02-23 10:00:00

LAGUNA HILLS, Calif., Feb. 23, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today initial patient treatments in the international multi-center REDUCE-HTN renal denervation clinical study for uncontrolled hypertension. REDUCE-HTN is a non-randomized, prospective, single cohort, 64-patient clinical study designed to validate the clinical performance of the Vessix V2 Renal Denervation System(TM) for...

2012-02-13 05:00:00

LAGUNA HILLS, Calif., Feb. 13, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that it will make its first detailed public presentation of preclinical data relating to its new V2 Renal Denervation System(TM) on Saturday, February 18, 2012 at the TRenD Workshop 2012, in Frankfurt, Germany. The presentation, titled "Percutaneous RF balloon-mediated renal denervation in under a minute: The V2...

2012-01-18 14:36:00

LAGUNA HILLS, Calif., Jan. 18, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that the first public presentation of its new percutaneous V2 Renal Denervation System(TM) for the treatment of medication-resistant hypertension will be made at LINC 2012 in Leipzig, Germany on Thursday, January 26, 2012. Renal denervation is a new percutaneous catheter-based technique for the treatment...

2011-08-03 09:00:00

LAGUNA HILLS, Calif., Aug. 3, 2011 /PRNewswire/ -- Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.), a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that it has completed a $23 million Series B preferred stock financing. The lead investor in the financing round was Edmond de Rothschild Investment Partners (EdRIP) of Paris, France. Also participating in the financing was NY-based OrbiMed Advisors, CDF Dinova Venture...